How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Disintegrating Agent Market
- By Type of Disintegrating Agent: Starch and Starch Derivatives, Cellulose and Cellulose Derivatives, Cross-linked Polyvinylpyrrolidone (Crospovidone), Sodium Starch Glycolate, Croscarmellose Sodium
- By Formulation Type: Tablet, Capsule, Granules, Powder, Oral Disintegrating Films
- By Application: Pharmaceuticals, Nutraceuticals, Veterinary Medicine, Cosmetics
- By Route of Administration: Oral, Buccal, Sublingual
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Starch and Starch Derivatives leads By Type of Disintegrating Agent at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Disintegrating Agent Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Type of Disintegrating Agent 5
Formulation Type 5
Application 4
Route of Administration 3
Companies profiled
BASF SE
Dow Inc.
Evonik Industries AG
Ashland Global Holdings Inc.
JRS Pharma
Roquette Frères
Colorcon Inc.
DuPont de Nemours Inc.
Cargill
Incorporated
Mingtai Chemical Co. Ltd.
Aarti Industries Ltd.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Dow Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Evonik Industries AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ashland Global Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →JRS Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Roquette Frères
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Colorcon Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →DuPont de Nemours Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cargill
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mingtai Chemical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Aarti Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Acme-Hardesty Co.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Jubilant Life Sciences Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Nouryon
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Gujarat Alkalies and Chemicals Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,464M by 2033 · 3.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Starch and Starch Derivatives45.1
- Cellulose and Cellulose Derivatives11.6
- Cross-linked Polyvinylpyrrolidone (Crospovidone)16.4
- Sodium Starch Glycolate14.0
- Croscarmellose Sodium12.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$370.7M → $542.5M · 4.9%
Europe$258.4M → $365.8M · 4.4%
Asia Pacific$235.9M → $316.6M · 3.7%
Latin America$146.0M → $171.1M · 2.0%
Middle East and Africa$112.3M → $162.5M · 4.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.312026
3.332027
3.332028
3.352029
3.372030
3.372031
3.392032
3.402033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BASF SE15.1
- Dow Inc.22.2
- Evonik Industries AG8.8
- Ashland Global Holdings Inc.9.7
- JRS Pharma11.2
- Roquette Frères5.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Type of Disintegrating Agent27.6%
Formulation Type24.1%
Application22.1%
Route of Administration26.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.8
- Europe23.5
- Asia Pacific20.3
- Latin America11.0
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BASF SE | 95 | 76 | 78 | 85 | 97 | 80 | 85 |
| Dow Inc. | 87 | 72 | 91 | 92 | 77 | 90 | 85 |
| Evonik Industries AG | 79 | 67 | 74 | 74 | 67 | 78 | 73 |
| Ashland Global Holdings Inc. | 81 | 76 | 63 | 70 | 68 | 61 | 70 |
| JRS Pharma | 54 | 60 | 67 | 56 | 62 | 67 | 61 |
| Roquette Frères | 52 | 53 | 57 | 61 | 52 | 58 | 56 |
| Colorcon Inc. | 55 | 61 | 44 | 61 | 43 | 53 | 53 |
| DuPont de Nemours Inc. | 46 | 58 | 37 | 37 | 48 | 37 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BASF SE
- Dow Inc.
- Evonik Industries AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BASF SE | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Dow Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Evonik Industries AG | ◐ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Ashland Global Holdings Inc. | ✓ | ✓ | − | ◐ | ◐ | − |
| JRS Pharma | − | ◐ | ◐ | − | ◐ | − |
| Roquette Frères | ◐ | ◐ | − | ◐ | ◐ | − |
| Colorcon Inc. | − | − | − | ◐ | ◐ | ◐ |
| DuPont de Nemours Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BASF SE85
2Dow Inc.85
3Evonik Industries AG73
4Ashland Global Holdings Inc.70
5JRS Pharma61
6Roquette Frères56
7Colorcon Inc.53
8DuPont de Nemours Inc.44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
BASF SEDow Inc.
Challenger2
Strong scale, closing on the leaders.
Evonik Industries AGAshland Global Holdings Inc.
Contender1
Focused players with pockets of strength.
JRS Pharma
Niche3
Specialists in a single segment or region.
Roquette FrèresColorcon Inc.DuPont de Nemours Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Type of Disintegrating Agent in North America, then scale across Disintegrating Agent Market — a $459M beachhead inside a $6.08B market.
Beachhead (SOM)$459Mobtainable near-term
Serviceable (SAM)$2.45Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Starch and Starch Derivatives
Best fit — highest urgency & budget in Type of Disintegrating Agent.
Economic buyer79 fit
Cellulose and Cellulose Derivatives
Strong fit — clear ROI and a fast path to value.
End user67 fit
Cross-linked Polyvinylpyrrolidone (Crospovidone)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Type of Disintegrating Agent in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Formulation Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Type of Disintegrating Agent leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Disintegrating Agent Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified20%
Evaluation14%
Closed-won6%
$9.9KCAC
$35KLTV
3.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Disintegrating Agent Market is a durable-growth opportunity — $9.70B by 2033, compounding at 7.2%.
TAM · 2025$5.56Btoday
TAM · 2033$9.70Bforecast
CAGR7.2%2027–2033
Cumulative$67.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.70BTotal addressable market
SAM$3.57BServiceable available market
SOM$749MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Type of Disintegrating Agent.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Type of Disintegrating Agent moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.70BLarge & growingTAM by 2033 at 7.2% CAGR
$3.57BServiceable nowreachable with today’s model
$749MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.57BBear4.7% CAGR
$9.70BBase7.2% CAGR
$12.4BBull9.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Formulation Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Disintegrating Agent Market — a $7.30B market by 2033. Plan: grow share from 7.4% to 12.4%.
Market size · 2033$7.30Btotal addressable
Market CAGR5.7%2027–2033
Target share12.4%from 7.4% today
Revenue ambition$906Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.4% | 12.4% | At risk |
| Revenue | $576M | $906M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.4% | 40.5% | At risk |
| Customer retention | 90.3% | 96.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Type of Disintegrating Agent
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Formulation Type capability
A defensible second engine — invest in Formulation Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Type of Disintegrating Agent share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Formulation Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $94M capacity & capability investment
- Greenlight bolt-on M&A in Formulation Type
- Authorise North America expansion plan
- Fund R&D program for Type of Disintegrating Agent leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Disintegrating Agent Market conversation — a $3.01B market you can size, segment and defend in minutes.
Market size · 2033$3.01Btotal opportunity
Growth5.4%CAGR to 2033
Addressable buyers1,718+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Type of Disintegrating Agent
Goal Grow share in Type of Disintegrating Agent
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 3 mopayback period
$48K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
BASF SEDow Inc.Evonik Industries AGAshland Global Holdings Inc.JRS PharmaRoquette FrèresColorcon Inc.DuPont de Nemours Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Disintegrating Agent Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Disintegrating Agent Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Incretin-Based Drugs Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportMinimally Invasive Neurosurgery Devices Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportMicro-ultrasound Systems Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportMicrosclerotherapy Treatment Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCulture Media of Microbiology Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportMicrobiology Culture Market
Market size, share, segmentation and regional forecast.
$375M market · 2025 base year
View reportMicrobial Fermentation Technology Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportMeningococcal Disease Drugs Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportMeningococcal Disease Treatment Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportDrugs for Melanoma Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportMedication Management System Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportMedication Management Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.